Scholarlink

Purpose <p>To investigate the biological function and the underlying mechanism of CD39 in cholangiocarcinoma.</p> Methods <p>Quantitative reverse transcription PCR (RT-qPCR), western blot (WB), and immunohistochemistry staining was used to evaluate the expression level of CD39 in cholangiocarcinoma. Kaplan–Meier and Cox hazard ratio regression analyses were implicated to evaluate the prognostic significance of CD39. Cell counting kit-8 (CCK-8) was carried out to evaluate the proliferative capacity, while transwell assay was used to detect the migration and invasion ability. In addition, B-NDG mice were used for the in vivo assay. The potential protein binding with the CD39 was identified through co-immunoprecipitation.</p> Results <p>CD39 was aberrantly expressed in the tumor tissue and cholangiocarcinoma cell lines. CD39 was identified as an independent poor prognostic factor in cholangiocarcinoma. In addition, in vitro and in vivo data indicated that the knockdown of CD39 could suppress the proliferation, migration, and invasion ability. The opposite results were observed when CD39 was overexpressed. Mechanistically, CD39 could bind with Annexin A2 (ANXA2), which influences the phosphorylation level of ANXA2 at the Tyr24 site, thereby promoting the activation of PI3K/AKT signaling, which resulted in the biological change in cholangiocarcinoma.</p> Conclusion <p>CD39 was identified as an independent prognostic factor of poor overall survival for patients with cholangiocarcinoma. In terms of the biological role of CD39, our data indicated that CD39 promoted the progression and metastasis of cholangiocarcinoma through binding with ANXA2, and through activating the PI3K/AKT signaling. In brief, CD39 is a potential prognostic factor and therapeutical target for cholangiocarcinoma.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The aberrant expression of CD39 is associated with the dismal outcome of patients with cholangiocarcinoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年2月25日

查看全文
  • Bohao Zheng,
  • Sheng Shen,
  • Jiwen Wang,
  • Wentao Sun,
  • Wenze Wan,
  • Jiaying Liu,
  • Dexiang Zhang,
  • Xiaoling Ni,
  • Tao Suo,
  • Han Liu,
  • Xiaojian Ni,
  • Houbao Liu

摘要

Purpose

To investigate the biological function and the underlying mechanism of CD39 in cholangiocarcinoma.

Methods

Quantitative reverse transcription PCR (RT-qPCR), western blot (WB), and immunohistochemistry staining was used to evaluate the expression level of CD39 in cholangiocarcinoma. Kaplan–Meier and Cox hazard ratio regression analyses were implicated to evaluate the prognostic significance of CD39. Cell counting kit-8 (CCK-8) was carried out to evaluate the proliferative capacity, while transwell assay was used to detect the migration and invasion ability. In addition, B-NDG mice were used for the in vivo assay. The potential protein binding with the CD39 was identified through co-immunoprecipitation.

Results

CD39 was aberrantly expressed in the tumor tissue and cholangiocarcinoma cell lines. CD39 was identified as an independent poor prognostic factor in cholangiocarcinoma. In addition, in vitro and in vivo data indicated that the knockdown of CD39 could suppress the proliferation, migration, and invasion ability. The opposite results were observed when CD39 was overexpressed. Mechanistically, CD39 could bind with Annexin A2 (ANXA2), which influences the phosphorylation level of ANXA2 at the Tyr24 site, thereby promoting the activation of PI3K/AKT signaling, which resulted in the biological change in cholangiocarcinoma.

Conclusion

CD39 was identified as an independent prognostic factor of poor overall survival for patients with cholangiocarcinoma. In terms of the biological role of CD39, our data indicated that CD39 promoted the progression and metastasis of cholangiocarcinoma through binding with ANXA2, and through activating the PI3K/AKT signaling. In brief, CD39 is a potential prognostic factor and therapeutical target for cholangiocarcinoma.